Measles Cases In The U.S. Just Hit 1,000. RFK Jr. Still Isn't Taking It Seriously.
Cases of measles in the U.S. surpassed 1,000 for just the second time in 30 years this week. Health and Human Services Secretary Robert F. Kennedy Jr. still isn't taking it seriously.
The deadly and fast-spreading outbreak that first started in western Texas in January has spread to at least 31 states, with 1,001 cases in total reported, according to Friday data from the Centers for Disease Control and Prevention.
Texas currently has the most cases at 709. Three unvaccinated people have died, including two school-aged children from Texas. Data from the CDC shows that 96% of cases in the U.S. came from people who are unvaccinated or whose vaccination status is unknown. More than 120 people have been hospitalized.
As the onslaught continues, Kennedy ― an anti-vaccine conspiracy theorist who now heads the nation's top health agency ― has routinely downplayed the deadly spread, including promoting a range of unproven treatments.
After the death of a 6-year-old boy in February, Kennedy said the child's death was 'not unusual.'
'We have measles outbreaks every year,' he said at the time.
But this spread is unlike others the U.S. has previously seen, becoming the second-highest case count in 25 years.
After facing criticism, Kennedy slightly walked back his comments after attending the funeral of an 8-year-old Texas girl who died from measles at the start of April.
'The most effective way to prevent the spread of measles is the MMR vaccine,' he posted on X.
But since then, Kennedy has continued to downplay the continued spread of measles and the effectiveness of the MMR vaccine, which treats measles, mumps and rubella.
At the end of April, Kennedy baselessly claimed that the measles vaccine 'contains a lot of aborted fetus debris and DNA particles.' Less than a week later, he went on a TV appearance to tell parents to 'do your own research' on vaccines. Kennedy did not specify any sources parents should look at.
And earlier this month, Kennedy announced the HHS would look into using vitamins as a possible treatment for measles.
The directive comes because Kennedy and department officials 'recognize that some individuals and communities across the U.S. may choose not to vaccinate,' HHS spokesperson Andrew Nixon said in a statement.
Kennedy also announced this month that the HHS will now require placebo testing for 'all new vaccines.' Health experts warn that the changes could seriously delay a vaccine's release and lead to making vaccines less accessible. It could also create situations in which someone needing a life-saving vaccine could instead receive a placebo, which is an inert substance that does not contain the vaccine.
'You are watching the gradual dissolution of the vaccine infrastructure in this country,' Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, told The Washington Post. 'The goal is to make vaccines less available and less affordable.'
Making matters worse, thousands of workers at the HHS were laid off earlier this year as part of President Donald Trump's continued purge of civil servants. On Monday, more than a dozen states sued the Trump administration over the firings, arguing that the cuts brought important work at the agency to a 'sudden halt.'
Despite Kennedy's seemingly-lax response to the spread and his continued denigration of vaccines, the CDC still recommends vaccinations as the best way to prevent measles.
'Measles is an airborne, extremely infectious, and potentially severe rash illness,' the CDC's website says. 'Before the measles vaccine was introduced, an estimated 48,000 people were hospitalized and 400–500 people died in the United States each year.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
27 minutes ago
- CBS News
Cook County jury awards $20.5 million to family of girl who died from toxic levels of morphine
A Cook County jury awarded more than $20 million in damages to the family of an 11-year-old girl who died from toxic levels of morphine. In October 2020, Ava Wilson was recovering from leukemia when she went for a follow-up appointment at Advocate Children's Hospital. During her appointment, she was crying from pain, and had difficulty walking, according to her family's attorneys. Lab tests revealed she had low platelet counts, low blood cell counts, high liver enzymes, and low blood pressure. She was discharged from Advocate Children's Hospital with instructions to take 15 milligrams of morphine every four hours, triple the amount of her previous prescriptions. A nurse practitioner also increased her gabapentin prescription. Approximately 36 hours after getting home, she died in her sleep from acute drug toxicity of several substances, including lethal levels of morphine in her system at the time of her death. Her family's attorneys said the hospital should have admitted Ava to the hospital to get her blood pressure under control and treat the cause of her pain, but simply sent her home with excessive pain medications. "Ava's body was yelling out to these clinicians, 'help me!', and they just ignored it," attorney Matthew Williams said. After a civil trial, a jury awarded her family $20.5 million in damages. "While nothing will ease the depth of Ava's loved ones' pain, the family appreciates that the jury recognized that Ava's death was preventable and that she should still be with them today," attorney Aaron Boeder said.
Medscape
29 minutes ago
- Medscape
Fast Five Quiz: Late-Onset Pompe Disease
Multiple genetic variants have been associated with LOPD. However, the c.-32-13T>G splice site variant is found in up to 90% of adults and 50% of pediatric patients. Patients with LOPD often have compound heterozygous genotypes, with one allele carrying the common c.-32-13T>G splice-site variant and the other harboring a more deleterious GAA mutation (eg, nonsense, frameshift, or large deletion). Other variants— such as and c.1935C>A — are more commonly seen in infantile forms of Pompe disease. Learn more about the pathophysiology of LOPD. Diagnosis of LOPD typically follows a two-step approach: first, measuring GAA enzyme activity (often via dried blood spot assay) followed by confirmatory molecular genetic testing to identify pathogenic GAA variants. Although once considered a first-line diagnostic tool for LOPD, muscle biopsy is no longer preferred due to its invasive nature and the non-specificity of histologic findings. Muscle biopsy may still be considered in rare, ambiguous cases when enzyme and genetic testing are inconclusive or conflicting. CK levels might be elevated in some patients but are nonspecific and primarily serve to raise clinical suspicion. Learn more about the workup for LOPD. Enzyme replacement therapy (ERT) has significantly changed the natural history of the disease by improving survival and stabilizing motor and respiratory function. However, key limitations in skeletal muscle uptake and variability in clinical response remain. This is due to low expression of the mannose-6-phosphate receptor in muscle tissue, which hampers enzyme internalization. As a result, patients might experience a limited or plateaued response. Newer approaches, including modified ERT and gene therapy, are being developed to address this issue. High toxicity to cardiac muscle, uniform patient response, and development of cardiac hypertrophy have not been reported as key limitations. Learn more about treatment options for LOPD. NBS programs have reshaped the understanding of Pompe disease, particularly LOPD. A significant proportion of screen-positive newborns harbor genetic variants associated with LOPD, including pseudo deficiency alleles and variants of uncertain significance. These individuals are often asymptomatic at birth and might not develop symptoms for years, if at all. This has raised important clinical questions around monitoring, counseling, and when (or whether) to initiate therapy; expanded screening has also revealed that the true prevalence of LOPD might be higher than historical estimates suggested. Learn more about the management of LOPD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication. Lead image: UCSF/Science Source
CNN
37 minutes ago
- CNN
Kennedy names new members of CDC vaccine advisory panel days after removing previous advisers
Just two days after retiring the entirety of the US Centers for Disease Control and Prevention's vaccine advisory panel, US Health and Human Services Secretary Robert F. Kennedy Jr. has appointed several prominent critics of the government's Covid-19 response to that committee. He announced eight new members of the CDC's Advisory Committee on Immunization Practices, or ACIP, on Wednesday. Kennedy had said Monday that the previous 17-member panel that makes recommendations on who should get vaccines and when was rife with conflicts of interest and that he would appoint new 'highly credentialed' experts in time for the panel's June 25 meeting, at which the members are expected to discuss guidance for Covid-19 and HPV shots, among others. In a statement Wednesday, Kennedy said the reassembled panel will demand 'definitive safety and efficacy data before making any new vaccine recommendations, but will also review data for the current vaccine schedule as well.' The eight new ACIP members include Dr. Robert Malone, a biochemist who made early innovations in the field of messenger RNA but in more recent years has been a vocal critic of mRNA technology in Covid-19 vaccines. The CDC recently narrowed its recommendations for mRNA Covid-19 shots, but some advocates in the Make America Healthy Again space have pressed Kennedy to go further and bar the vaccines entirely. Another new member is Dr. Martin Kulldorff, a biostatistician and epidemiologist who co-authored an October 2020 strategy on herd immunity known as the Great Barrington Declaration with Dr. Jay Bhattacharya, now director of the US National Institutes of Health. Both Malone's and Kulldorff's names were circulated early in the second Trump administration as potential advisers on ACIP or other panels, according to a person familiar with the process who requested anonymity because they weren't authorized to speak with CNN. Kennedy also chose Dr. James Pagano, an emergency medicine physician he described as a 'strong advocate for evidence-based medicine' who has served on hospital committees and medical executive boards. Dr. Retsef Levi, an MIT professor who has published studies on mRNA vaccines and cardiovascular events, is also joining the panel. Levi is a professor of operations management. Several of the new members have served in federal health agencies previously, including Dr. Joseph Hibbeln, a former acting chief of the NIH's section on nutritional neurosciences. Dr. Cody Meissner, a Dartmouth professor of pediatrics who also signed the Great Barrington Declaration, has previously served on ACIP and on the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee. Dr. Vicky Pebsworth, the Pacific region director of the National Association of Catholic Nurses, also served on the FDA committee and on a national panel reviewing the 2009 H1N1 swine flu vaccine. Dr. Michael Ross, a professor of obstetrics and gynecology at George Washington University and Virginia Commonwealth University, has previously served on the CDC's Advisory Committee for the Prevention of Breast and Cervical Cancer. Kennedy also nodded in his statement to Ross' 'continued service on biotech and healthcare boards.' The private equity company Havencrest, in which Ross is an operating partner, describes him on its site as a 'serial CEO' who has served on the boards of several biotechnology companies.
